The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 11, 2022

Filed:

Nov. 28, 2016
Applicant:

Maxwell Biotech Group Ltd., Moscow, RU;

Inventors:

Ekaterina Alekseevna Ivanova, Moscow, RU;

Alexander Karpeisky, Lafayette, CO (US);

Shawn P. Zinnen, Denver, CO (US);

Lisa Lynn Caralli, Del Mar, CA (US);

Rina Diana Fong, San Diego, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/19 (2006.01); A61K 31/663 (2006.01); A61K 31/7068 (2006.01); A61K 47/02 (2006.01); A61P 35/04 (2006.01);
U.S. Cl.
CPC ...
A61K 9/19 (2013.01); A61K 31/663 (2013.01); A61K 31/7068 (2013.01); A61K 47/02 (2013.01); A61P 35/04 (2018.01);
Abstract

The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.


Find Patent Forward Citations

Loading…